282 related articles for article (PubMed ID: 29671786)
1. HIV Vaccination: A Roadmap among Advancements and Concerns.
Trovato M; D'Apice L; Prisco A; De Berardinis P
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29671786
[TBL] [Abstract][Full Text] [Related]
2. Comparative Immunogenicity of Evolved V1V2-Deleted HIV-1 Envelope Glycoprotein Trimers.
Bontjer I; Melchers M; Tong T; van Montfort T; Eggink D; Montefiori D; Olson WC; Moore JP; Binley JM; Berkhout B; Sanders RW
PLoS One; 2013; 8(6):e67484. PubMed ID: 23840716
[TBL] [Abstract][Full Text] [Related]
3. Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines.
Excler JL; Ake J; Robb ML; Kim JH; Plotkin SA
Clin Vaccine Immunol; 2014 Aug; 21(8):1023-36. PubMed ID: 24920599
[TBL] [Abstract][Full Text] [Related]
4. The Hard Way towards an Antibody-Based HIV-1 Env Vaccine: Lessons from Other Viruses.
Ringel O; Vieillard V; Debré P; Eichler J; Büning H; Dietrich U
Viruses; 2018 Apr; 10(4):. PubMed ID: 29662026
[TBL] [Abstract][Full Text] [Related]
5. Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses.
Beltran-Pavez C; Bontjer I; Gonzalez N; Pernas M; Merino-Mansilla A; Olvera A; Miro JM; Brander C; Alcami J; Sanders RW; Sanchez-Merino V; Yuste E
J Virol; 2022 Jan; 96(1):e0134321. PubMed ID: 34668778
[TBL] [Abstract][Full Text] [Related]
6. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
7. Structural Insights from HIV-Antibody Coevolution and Related Immunization Studies.
Zhou JO; Ton T; Morriss JW; Nguyen D; Fera D
AIDS Res Hum Retroviruses; 2018 Sep; 34(9):760-768. PubMed ID: 29984587
[TBL] [Abstract][Full Text] [Related]
8. Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus.
van Diepen MT; Chapman R; Douglass N; Galant S; Moore PL; Margolin E; Ximba P; Morris L; Rybicki EP; Williamson AL
J Virol; 2019 Apr; 93(8):. PubMed ID: 30760570
[TBL] [Abstract][Full Text] [Related]
9. A Novel MVA-Based HIV Vaccine Candidate (MVA-gp145-GPN) Co-Expressing Clade C Membrane-Bound Trimeric gp145 Env and Gag-Induced Virus-Like Particles (VLPs) Triggered Broad and Multifunctional HIV-1-Specific T Cell and Antibody Responses.
Perdiguero B; Sánchez-Corzo C; Sorzano COS; Saiz L; Mediavilla P; Esteban M; Gómez CE
Viruses; 2019 Feb; 11(2):. PubMed ID: 30781504
[TBL] [Abstract][Full Text] [Related]
10. Broadly neutralizing antibodies and vaccine design against HIV-1 infection.
Wang Q; Zhang L
Front Med; 2020 Feb; 14(1):30-42. PubMed ID: 31858368
[TBL] [Abstract][Full Text] [Related]
11. Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
Subbaraman H; Schanz M; Trkola A
Retrovirology; 2018 Jul; 15(1):52. PubMed ID: 30055627
[TBL] [Abstract][Full Text] [Related]
12. Structural insights on the role of antibodies in HIV-1 vaccine and therapy.
West AP; Scharf L; Scheid JF; Klein F; Bjorkman PJ; Nussenzweig MC
Cell; 2014 Feb; 156(4):633-48. PubMed ID: 24529371
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
[TBL] [Abstract][Full Text] [Related]
14. Cross-Linking of a CD4-Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
Shen X; Bogers WM; Yates NL; Ferrari G; Dey AK; Williams WT; Jaeger FH; Wiehe K; Sawant S; Alam SM; LaBranche CC; Montefiori DC; Martin L; Srivastava I; Heeney J; Barnett SW; Tomaras GD
J Virol; 2017 Oct; 91(19):. PubMed ID: 28490585
[TBL] [Abstract][Full Text] [Related]
15. Employing Broadly Neutralizing Antibodies as a Human Immunodeficiency Virus Prophylactic & Therapeutic Application.
Ding C; Patel D; Ma Y; Mann JFS; Wu J; Gao Y
Front Immunol; 2021; 12():697683. PubMed ID: 34354709
[TBL] [Abstract][Full Text] [Related]
16. Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies.
Ahmed Y; Tian M; Gao Y
AIDS Res Ther; 2017 Sep; 14(1):50. PubMed ID: 28893278
[TBL] [Abstract][Full Text] [Related]
17. Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies.
Mabvakure BM; Scheepers C; Garrett N; Abdool Karim S; Williamson C; Morris L; Moore PL
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567996
[TBL] [Abstract][Full Text] [Related]
18. Germinal Center Lymphocyte Ratios and Successful HIV Vaccines.
Gonzalez-Figueroa P; Roco JA; Vinuesa CG
Trends Mol Med; 2017 Feb; 23(2):95-97. PubMed ID: 28089302
[TBL] [Abstract][Full Text] [Related]
19. Lessons learned from HIV-1 vaccine trials: new priorities and directions.
McMichael AJ; Haynes BF
Nat Immunol; 2012 Apr; 13(5):423-7. PubMed ID: 22513323
[TBL] [Abstract][Full Text] [Related]
20. HIV Vaccines: One Step Closer.
Low MSY; Tarlinton D
Trends Mol Med; 2017 Jan; 23(1):1-3. PubMed ID: 27889424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
